Amgen

Amgen expands pact with Amazon to usher drug manufacturing into the AI era
Amgen expands pact with Amazon to usher drug manufacturing into the AI era
Fierce Pharma
Amgen
artificial intelligence
Amazon
drug manufacturing
Flag link:
PostEra Announces a Research Collaboration with Amgen to Discover Small Molecule Therapeutics using Artificial Intelligence
PostEra Announces a Research Collaboration with Amgen to Discover Small Molecule Therapeutics using Artificial Intelligence
PR Newswire
Amgen
PostEra
artificial intelligence
drug discovery
Flag link:
Amgen reports data from Sjögren’s Syndrome treatment trial
Amgen reports data from Sjögren’s Syndrome treatment trial
Clinical Trials Arena
Amgen
clinical trials
dazodalibep
Sjögren’s syndrome
Flag link:
Amgen scores FDA approval for Stelara biosimilar
Amgen scores FDA approval for Stelara biosimilar
Pharmaceutical Technology
Amgen
Stelara
biosimilars
JNJ
FDA
Wezlana
Flag link:
'This field is in its infancy': Amgen noncommittal on oral obesity med until phase 1 data arrive
'This field is in its infancy': Amgen noncommittal on oral obesity med until phase 1 data arrive
Fierce Biotech
Amgen
obesity
AMG-786
Flag link:
Amgen stops trial of Teneobio cancer candidate, taking $650M BiTE out of earnings
Amgen stops trial of Teneobio cancer candidate, taking $650M BiTE out of earnings
Fierce Biotech
Amgen
earnings
Teneobio
bispecifics
Flag link:
Amgen plans to lay off 350 former Horizon employees after $28B buyout
Amgen plans to lay off 350 former Horizon employees after $28B buyout
Fierce Pharma
Amgen
Horizon Therapeutics
layoffs
M&A
Flag link:
Merck's early KRAS data suggest combination-friendly safety
Merck's early KRAS data suggest combination-friendly safety
Fierce Biotech
Merck
ESMO
KRAS inhibitors
Amgen
Lumakras
Flag link:
Amgen’s T-Cell Engager Shows Phase II Promise in Tough to Treat Lung Cancer
Amgen’s T-Cell Engager Shows Phase II Promise in Tough to Treat Lung Cancer
BioSpace
Amgen
bispecific antibodies
T-cell engager
tarlatamab
clinical trials
Flag link:
Amgen Completes $27.8B Horizon Acquisition Following FTC Challenge
Amgen Completes $27.8B Horizon Acquisition Following FTC Challenge
BioSpace
Amgen
Horizon Therapeutics
FTC
M&A
Flag link:
Amgen's Lumakras flunks FDA expert meeting, but market withdrawal looks unlikely for now
Amgen's Lumakras flunks FDA expert meeting, but market withdrawal looks unlikely for now
Fierce Pharma
Amgen
Lumakras
FDA
KRAS inhibitors
Flag link:
FDA Says ‘Systemic Bias’ in Amgen’s Lumakras Trial Ahead of Adcomm Meeting
FDA Says ‘Systemic Bias’ in Amgen’s Lumakras Trial Ahead of Adcomm Meeting
BioSpace
Amgen
Lumakras
non-small cell lung cancer
FDA
Flag link:
FDA staff says late-stage data 'not enough' for Amgen's lung cancer drug
FDA staff says late-stage data 'not enough' for Amgen's lung cancer drug
Reuters
Amgen
FDA
Lumakras
lung cancer
Flag link:
5 FDA decisions to watch in the fourth quarter
5 FDA decisions to watch in the fourth quarter
BioPharma Dive
FDA
Alnylam
Onpattro
ATTR amyloidosis
Vertex Pharmaceuticals
CRISPR Therapeutics
exa-cel
Bluebird Bio
Zynteglo
sickle cell disease
Bristol Myers Squibb
2seventy bio
Abecma
Multiple Myeloma
Amgen
Lumakras
non-small cell lung cancer
Pfizer
estrasimod
ulcerative colitis
Flag link:
Neumora Therapeutics stock surges as Amgen confirmed as major shareholder
Neumora Therapeutics stock surges as Amgen confirmed as major shareholder
Proactive Investors
Amgen
Neumora
IPOs
Flag link:
Amgen unveils Partners of Choice oncology network
Amgen unveils Partners of Choice oncology network
Medical Marketing and Media
Amgen
expert panels
oncology
cancer
Flag link:
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans
BioSpace
Amgen
Horizon Therapeutics
FTC
antitrust
M&A
Flag link:
FTC allows Amgen’s $27.8B purchase of Horizon to proceed
FTC allows Amgen’s $27.8B purchase of Horizon to proceed
Medical Marketing and Media
FTC
Amgen
Horizon Therapeutics
M&A
Flag link:
FTC Temporarily Withdraws Challenge to $27.8B Amgen-Horizon Deal
FTC Temporarily Withdraws Challenge to $27.8B Amgen-Horizon Deal
BioSpace
FTC
Amgen
Horizon Therapeutics
M&A
Flag link:
Amgen Presents Late-Breaking Phase 2 Olpasiran Data at ESC 2023
Amgen Presents Late-Breaking Phase 2 Olpasiran Data at ESC 2023
BioSpace
Amgen
cardiovascular disease
olpasiran
clinical trials
Flag link:

Pages